294 related articles for article (PubMed ID: 17138058)
1. sCD30, interleukin-1beta-converting enzyme and anti-Annexin V autoantibodies concentrations in heart transplant recipients.
Zeglen S; Zakliczyński M; Nozyński J; Rogala B; Zembala M
Transpl Immunol; 2006 Nov; 16(3-4):227-31. PubMed ID: 17138058
[TBL] [Abstract][Full Text] [Related]
2. The effects of HLA mismatching and immunosuppressive therapy on early rejection outcome in pediatric heart transplant recipients.
Herzberg GZ; Rossi AF; Courtney M; Gelb BD
J Heart Lung Transplant; 1998 Dec; 17(12):1195-200. PubMed ID: 9883760
[TBL] [Abstract][Full Text] [Related]
3. Soluble CD30 in renal transplant recipients: is it a good biomarker to predict rejection?
Azarpira N; Aghdaie MH; Malekpour Z
Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):31-6. PubMed ID: 20061689
[TBL] [Abstract][Full Text] [Related]
4. Soluble CD30 levels in recipients undergoing heart transplantation do not predict post-transplant outcome.
Ypsilantis E; Key T; Bradley JA; Morgan CH; Tsui S; Parameshwar J; Taylor CJ
J Heart Lung Transplant; 2009 Nov; 28(11):1206-10. PubMed ID: 19782609
[TBL] [Abstract][Full Text] [Related]
5. What else distinguishes cellular rejection grade 1A from 0? Annexin V and BCL in elective biopsies received from heart transplant recipients.
Zeglen S; Nozynski J; Wozniak-Grygiel E; Zakliczynski M; Kucewicz-Czech E; Laszewska A; Cichoracka A; Zembala M
Transplant Proc; 2009 Oct; 41(8):3198-201. PubMed ID: 19857709
[TBL] [Abstract][Full Text] [Related]
6. Soluble CD30 and HLA antibodies as potential risk factors for kidney transplant rejection.
Slavcev A; Lácha J; Honsová E; Sajdlová H; Lodererová A; Vitko S; Skibová J; Striz I
Transpl Immunol; 2005 Jun; 14(2):117-21. PubMed ID: 15935302
[TBL] [Abstract][Full Text] [Related]
7. High serum soluble CD30 does not predict acute rejection in liver transplant patients.
Matinlauri I; Höckerstedt K; Isoniemi H
Transplant Proc; 2006 Dec; 38(10):3601-4. PubMed ID: 17175343
[TBL] [Abstract][Full Text] [Related]
8. High pretransplantation soluble CD30 levels: impact in renal transplantation.
Giannoli C; Bonnet MC; Perrat G; Houillon A; Reydet S; Pouteil-Noble C; Villar E; Lefrançois N; Morelon E; Dubois V
Transplant Proc; 2007 Oct; 39(8):2574-5. PubMed ID: 17954178
[TBL] [Abstract][Full Text] [Related]
9. Pre-transplant soluble CD30 level as a predictor of not only acute rejection and graft loss but pneumonia in renal transplant recipients.
Wang D; Wu WZ; Chen JH; Yang SL; Wang QH; Zeng ZX; Tan JM
Transpl Immunol; 2010 Feb; 22(3-4):115-20. PubMed ID: 20036333
[TBL] [Abstract][Full Text] [Related]
10. Relative reductions in soluble CD30 levels post-transplant predict acute graft function in islet allograft recipients receiving three different immunosuppression protocols.
Hire K; Hering B; Bansal-Pakala P
Transpl Immunol; 2010 Aug; 23(4):209-14. PubMed ID: 20600901
[TBL] [Abstract][Full Text] [Related]
11. Plasma levels of soluble CD30 in kidney graft recipients as predictors of acute allograft rejection.
Ayed K; Abdallah TB; Bardi R; Abderrahim E; Kheder A
Transplant Proc; 2006 Sep; 38(7):2300-2. PubMed ID: 16980071
[TBL] [Abstract][Full Text] [Related]
12. Posttransplant soluble CD30 as a predictor of acute renal allograft rejection.
Kamali K; Abbasi MA; Farokhi B; Abbasi A; Fallah P; Seifee MH; Ghadimi N; Rezaie AR
Exp Clin Transplant; 2009 Dec; 7(4):237-40. PubMed ID: 20353374
[TBL] [Abstract][Full Text] [Related]
13. Does pretransplant soluble CD30 serum concentration affect deceased-donor kidney graft function 3 years after transplantation?
Kovac J; Arnol M; Vidan-Jeras B; Bren AF; Kandus A
Transplant Proc; 2008 Jun; 40(5):1357-61. PubMed ID: 18589105
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic validity of hepatocyte growth factor as marker for rejection in the follow-up of patients after heart transplantation.
Zwirska-Korczala K; Zakliczyński M; Berdowska A; Zembala M; Jochem J; Gajewska K
J Heart Lung Transplant; 2005 Apr; 24(4):411-5. PubMed ID: 15797741
[TBL] [Abstract][Full Text] [Related]
15. Soluble CD30 as a prognostic factor for outcome following renal transplantation.
Platt RE; Wu KS; Poole K; Newstead CG; Clark B
J Clin Pathol; 2009 Jul; 62(7):662-3. PubMed ID: 19561239
[TBL] [Abstract][Full Text] [Related]
16. Pre- and post-transplant anti-myosin and anti-heat shock protein antibodies and cardiac transplant outcome.
Morgun A; Shulzhenko N; Unterkircher CS; Diniz RV; Pereira AB; Silva MS; Nishida SK; Almeida DR; Carvalho AC; Franco M; Souza MM; Gerbase-DeLima M
J Heart Lung Transplant; 2004 Feb; 23(2):204-9. PubMed ID: 14761768
[TBL] [Abstract][Full Text] [Related]
17. Post-transplant increased levels of serum sCD30 is a marker for prediction of kidney allograft loss in a 5-year prospective study.
Delgado JC; Pavlov IY; Shihab FS
Transpl Immunol; 2009 Dec; 22(1-2):1-4. PubMed ID: 19772921
[TBL] [Abstract][Full Text] [Related]
18. Association between serum soluble CD30 and serum creatinine before and after renal transplantation.
López-Hoyos M; San Segundo D; Benito MJ; Fernández-Fresnedo G; Ruiz JC; Rodrigo E; Gómez-Alamillo C; Benito A; Arias M
Transplant Proc; 2008 Nov; 40(9):2903-5. PubMed ID: 19010142
[TBL] [Abstract][Full Text] [Related]
19. Value of soluble CD30 in liver transplantation.
Fábrega E; Unzueta MG; Cobo M; Casafont F; Amado JA; Romero FP
Transplant Proc; 2007 Sep; 39(7):2295-6. PubMed ID: 17889168
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of soluble CD30 as an immunologic marker in heart transplant recipients.
Spiridon C; Hunt J; Mack M; Rosenthal J; Anderson A; Eichhorn E; Magee M; Dewey T; Currier M; Nikaein A
Transplant Proc; 2006 Dec; 38(10):3689-91. PubMed ID: 17175368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
